Prospective, non-interventional, multicenter study of the intraocular pressure-lowering effects of prostaglandin analog/prostamide-containing therapies in previously treated patients with open-angle glaucoma or ocular hypertension

References

• ThamYCLiXWongTYQuigleyHAAungTChengCYGlobal prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysisOphthalmology2014121112081209024974815
   PubMed Web of Science ®Google Scholar
• Glaucoma Facts and Stats [webpage on the Internet]Glaucoma Research Foundation Website2015 Available from: http://www.glaucoma.org/glaucoma/glaucoma-facts-and-stats.phpAccessed May 24, 2016
   Google Scholar
• American Academy of OphthalmologyPreferred Practice Pattern: Primary Open-Angle GlaucomaSan Francisco, CAElsevier2016 Available from: www.aaojournal.org/article/S0161-6420(15)01276-2/pdfAccessed May 24, 2016
   Google Scholar
• European Glaucoma SocietyTerminology and Guidelines for Glaucoma4th ed2016 Available from: http://www.eugs.org/eng/EGS_guidelines4.aspAccessed May 24, 2016
   Google Scholar
• HeijlABengtssonBHymanLLeskeMCEarly Manifest Glaucoma Trial GroupNatural history of open-angle glaucomaOphthalmology2009116122271227619854514
   PubMed Web of Science ®Google Scholar
• WeinrebRNAungTMedeirosFAThe pathophysiology and treatment of glaucoma: a reviewJAMA2014311181901191124825645
   PubMed Web of Science ®Google Scholar
• LiuJHKripkeDFWeinrebRNComparison of the nocturnal effects of once-daily timolol and latanoprost on intraocular pressureAm J Ophthalmol2004138338939515364220
   PubMed Web of Science ®Google Scholar
• BrubakerRFSchoffEONauCBCarpenterSPChenKVandenburghAMEffects of AGN 192024, a new ocular hypotensive agent, on aqueous dynamicsAm J Ophthalmol20011311192411162974
   PubMed Web of Science ®Google Scholar
• GulatiVFanSZhaoMMaslonkaMAGangaharCTorisCBDiurnal and nocturnal variations in aqueous humor dynamics of patients with ocular hypertension undergoing medical therapyArch Ophthalmol2012130667768422332206
   PubMedGoogle Scholar
• TungJDTafreshiAWeinrebRNSlightJRMedeirosFALiuJHTwenty-four-hour effects of bimatoprost 0.01% monotherapy on intraocular pressure and ocular perfusion pressureBMJ Open201224e001106
   Web of Science ®Google Scholar
• OrzalesiNRossettiLInvernizziTBottoliAAutelitanoAEffect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertensionInvest Ophthalmol Vis Sci20004192566257310937568
   PubMed Web of Science ®Google Scholar
• BrandtJDCantorLBKatzLJEarly Manifest Glaucoma Trial GroupBimatoprost/timolol fixed combination: a 3-month double-masked, randomized parallel comparison to its individual components in patients with glaucoma or ocular hypertensionJ Glaucoma200817321121618414107
   PubMed Web of Science ®Google Scholar
• FeuerhakeCBuchholzPKimmichFEfficacy, tolerability and safety of the fixed combination of bimatoprost 0.03% and timolol 0.5% in a broad patient population: multicenter, open-label observational studyCurr Med Res Opin20092541037104319290780
   PubMed Web of Science ®Google Scholar
• LewisRAGrossRLSallKNGanfort Investigators Group IIThe safety and efficacy of bimatoprost/timolol fixed combination: a 1-year double-masked, randomized parallel comparison to its individual components in patients with glaucoma or ocular hypertensionJ Glaucoma201019642442619855289
   PubMed Web of Science ®Google Scholar
• Hommer A; Ganfort Investigators GroupIA double-masked, randomized, parallel comparison of a fixed combination of bimatoprost 0.03%/timolol 0.5% with non-fixed combination use in patients with glaucoma or ocular hypertensionEur J Ophthalmol20071715362
   Web of Science ®Google Scholar
• CentofantiMOddoneFGandolfiSComparison of Travoprost and Bimatoprost plus timolol fixed combinations in open-angle glaucoma patients previously treated with latanoprost plus timolol fixed combinationAm J Ophthalmol2010150457558020688314
   PubMed Web of Science ®Google Scholar
• CentofantiMOddoneFVetrugnoMEfficacy of the fixed combinations of bimatoprost or latanoprost plus timolol in patients uncontrolled with prostaglandin monotherapy: a multicenter, randomized, investigator-masked, clinical studyEur J Ophthalmol2009191667119123151
   PubMed Web of Science ®Google Scholar
• MackyTABimatoprost/timolol versus travoprost/timolol fixed combinations in an Egyptian population: a hospital-based prospective randomized studyJ Glaucoma201423856156623429621
   PubMed Web of Science ®Google Scholar
• MartinezASanchezMA comparison of the safety and intraocular pressure lowering of bimatoprost/timolol fixed combination versus latanoprost/timolol fixed combination in patients with open-angle glaucomaCurr Med Res Opin20072351025103217519068
   PubMed Web of Science ®Google Scholar
• MartinezASanchezMBimatoprost/timolol fixed combination vs latanoprost/timolol fixed combination in open-angle glaucoma patientsEye200923481081818535605
   PubMed Web of Science ®Google Scholar
• JothiRIsmailAMSenthamaraiRPalSA comparative study on the efficacy, safety, and cost-effectiveness of bimatoprost/timolol and dorzolamide/timolol combinations in glaucoma patientsIndian J Pharmacol201042636236521189906
   PubMed Web of Science ®Google Scholar
• ChengJWChengSWGaoLDLuGCWeiRLIntraocular pressure-lowering effects of commonly used fixed-combination drugs with timolol: a systematic review and meta-analysisPLoS One201279e4507923028770
   PubMed Web of Science ®Google Scholar
• YavaşGFKüsbeciTPolatOKaradaşMErmişSSİnanUUComparison of latanoprost, brimonidine tartrate, and bimatoprost plus timolol maleate in fixed combinationsTurk J Med Sci2013432321325
   Web of Science ®Google Scholar
• ParanhosAMendonçaMSilvaMJHyperemia reduction after administration of a fixed combination of bimatoprost and timolol maleate to patients on prostaglandin or prostamide monotherapyJ Ocul Pharmacol Ther201026661161521029020
   PubMed Web of Science ®Google Scholar
• European Medicined Agency [webpage on the Internet]Ganfort Authorisation Details Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000668/human_med_000804.jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d125Accessed March 1, 2017
   Google Scholar
• MichelessiMLindsleyKYuTLiTCombination medical treatment for primary open angle glaucoma and ocular hypertension: a network meta-analysisCochrane Database Syst Rev2014201411CD01136625774087
   PubMedGoogle Scholar
• KatzLJCohenJSBatoosinghALFelixCShuVSchiffmanRMTwelve-month, randomized, controlled trial of bimatoprost 0.01%, 0.0125%, and 0.03% in patients with glaucoma or ocular hypertensionAm J Ophthalmol20101494661671.e20346780
   PubMed Web of Science ®Google Scholar
• RossettiLGandolfiSTraversoCAn evaluation of the rate of non-responders to latanoprost therapyJ Glaucoma200615323824316778647
   PubMed Web of Science ®Google Scholar
• CantorLBHoopJMorganLWudunnDCatoiraYBimatoprost–Travoprost Study GroupIntraocular pressure-lowering efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertensionBr J Ophthalmol200690111370137316825272
   PubMed Web of Science ®Google Scholar
• DuBinerHCookeDDirksMStewartWCVanDenburghAMFelixCEfficacy and safety of bimatoprost in patients with elevated intraocular pressure: a 30-day comparison with latanoprostSurv Ophthalmol200145suppl 4S353S36011434938
   PubMed Web of Science ®Google Scholar
• GandolfiSSimmonsSTSturmRChenKVanDenburghAMBimatoprost Study Group 3Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertensionAdv Ther200118311012111571823
   PubMed Web of Science ®Google Scholar
• NoeckerRSDirksMSChoplinNTBimatoprost/Latanoprost Study GroupA six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucomaAm J Ophthalmol20031351556312504698
   PubMed Web of Science ®Google Scholar
• ParrishRKPalmbergPSheuWPXLT Study GroupA comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter studyAm J Ophthalmol2003135568870312719078
   PubMed Web of Science ®Google Scholar
• WaltersTRDuBinerHBCarpenterSPKhanBVanDenburghAMBimatoprost Circadian IOP Study Group24-Hour IOP control with once-daily bimatoprost, timolol gel-forming solution, or latanoprost: a 1-month, randomized, comparative clinical trialSurv Ophthalmol200449suppl 1S26S3515016559
   PubMed Web of Science ®Google Scholar
• KurtzSMannOIncidence of hyperemia associated with bimatoprost treatment in naïve subjects and in subjects previously treated with latanoprostEur J Ophthalmol200919340040319396785
   PubMed Web of Science ®Google Scholar
• DayDGSchacknowPNWandMTimolol 0.5%/dorzolamide 2% fixed combination vs timolol maleate 0.5% and unoprostone 0.15% given twice daily to patients with primary open-angle glaucoma or ocular hypertensionAm J Ophthalmol2003135213814312566015
   PubMed Web of Science ®Google Scholar
• KimTWKimMLeeEJJeoungJWParkKHIntraocular pressure-lowering efficacy of dorzolamide/timolol fixed combination in normal-tension glaucomaJ Glaucoma201423532933223377586
   PubMed Web of Science ®Google Scholar
• ParmaksizSYükselNKarabasVLOzkanBDemirciGCaglarYA comparison of travoprost, latanoprost, and the fixed combination of dorzolamide and timolol in patients with pseudoexfoliation glaucomaEur J Ophthalmol20061617380
   Web of Science ®Google Scholar
• LingZZhangMHuYSafety and efficacy of bimatoprost/timolol fixed combination in Chinese patients with open-angle glaucoma or ocular hypertensionChin Med J2014127590591024571886
   PubMed Web of Science ®Google Scholar
• BriefGLammichTNagelEPfennigsdorfSSpraulCWHoSFixed combination of bimatoprost and timolol in patients with primary open-angle glaucoma or ocular hypertension with inadequate IOP adjustmentClin Ophthalmol201041125112920957059
   PubMedGoogle Scholar
• LeskeMCHeijlAHusseinMEarly Manifest Glaucoma Trial GroupFactors for glaucoma progression and the effect of treatment: the Early Manifest Glaucoma TrialArch Ophthalmol20031211485612523884
   PubMedGoogle Scholar
• ChauhanBCMikelbergFSBalasziAGCanadian Glaucoma Study GroupCanadian Glaucoma Study: 2. risk factors for the progression of open-angle glaucomaArch Ophthalmol200812681030103618695095
   PubMedGoogle Scholar
• KimKEJeoungJWKimDMAhnSJParkKHKimSHLong-term follow-up in preperimetric open-angle glaucoma: progression rates and associated factorsAm J Ophthalmol2015159116016825448320
   PubMed Web of Science ®Google Scholar
• CumurcuTKilicRYologluSThe frequency of pseudoexfoliation syndrome in the middle Black Sea region of TurkeyEur J Ophthalmol20102061007101120544680
   PubMed Web of Science ®Google Scholar
• KiliçRSezerHComcaliSÜThe frequency of exfoliation syndrome in the Central Anatolia region of TurkeyJ Ophthalmol2014201413982625165574
   PubMed Web of Science ®Google Scholar
• YalazMOthmanINasKThe frequency of pseudoexfoliation syndrome in the eastern Mediterranean area of TurkeyActa Ophthalmol (Copenh)19927022092131609569
   PubMed Web of Science ®Google Scholar
• TastanSIyigunEBayerAAcikelCAnxiety, depression, and quality of life in Turkish patients with glaucomaPsychol Rep2010106234335720524533
   PubMed Web of Science ®Google Scholar
• WangSYSinghKLinSCPrevalence and predictors of depression among participants with glaucoma in a nationally representative population sampleAm J Ophthalmol2012154343644422789562
   PubMed Web of Science ®Google Scholar
• YochimBPMuellerAEKaneKDKahookMYPrevalence of cognitive impairment, depression, and anxiety symptoms among older adults with glaucomaJ Glaucoma201221425025421336151
   PubMed Web of Science ®Google Scholar
• AgorastosASkevasCMatthaeiMDepression, anxiety, and disturbed sleep in glaucomaJ Neuropsychiatry Clin Neurosci201325320521324026713
   PubMed Web of Science ®Google Scholar
• MabuchiFYoshimuraKKashiwagiKHigh prevalence of anxiety and depression in patients with primary open-angle glaucomaJ Glaucoma200817755255718854732
   PubMed Web of Science ®Google Scholar
• ZhouCQianSWuPQiuCAnxiety and depression in Chinese patients with glaucoma: sociodemographic, clinical, and self-reported correlatesJ Psychosom Res2013751758223751243
   PubMed Web of Science ®Google Scholar
• McCambridgeJWittonJElbourneDRSystematic review of the Hawthorne effect: new concepts are needed to study research participation effectsJ Clin Epidemiol201467326727724275499
   PubMed Web of Science ®Google Scholar
• HommerAMohammed RamezOBurchertMKimmichFIOP-lowering efficacy and tolerability of preservative-free tafluprost 0.0015% among patients with ocular hypertension or glaucomaCurr Med Res Opin20102681905191320553122
   PubMed Web of Science ®Google Scholar
• CrichtonACNixonDRSimonyiSAn observational study of bimatoprost 0.01% in patients on prior intraocular pressure-lowering therapy: the Canadian Lumigan((R)) RC Early Analysis Review (CLEAR) trialClin Ophthalmol201481031103824920879
   PubMedGoogle Scholar
• KookMSSimonyiSSohnYHKimCYParkKHBimatoprost 0.01% for previously treated patients with open-angle glaucoma or ocular hypertension in the Korean clinical settingJpn J Ophthalmol201559532533426202440
   PubMed Web of Science ®Google Scholar
• ChenYYWangTHLiuCTolerability and efficacy of bimatoprost 0.01% in patients with open-angle glaucoma or ocular hypertension evaluated in the Taiwanese clinical setting: the Asia Pacific Patterns from Early Access of Lumigan 0.01% (APPEAL Taiwan) studyBMC Ophthalmol201616116227633513
   PubMed Web of Science ®Google Scholar